Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)
China · Delayed Price · Currency is CNY 19.46
+1.00 (5.42%)
At close: Mar 6, 2026
Cabio Biotech (Wuhan) Market Cap
Cabio Biotech (Wuhan) has a market cap or net worth of 3.25 billion as of March 6, 2026. Its market cap has decreased by -5.55% in one year.
Market Cap
3.25B
Enterprise Value
3.10B
Revenue
574.88M
Ranking
n/a
PE Ratio
20.70
Stock Price
19.46
Market Cap Chart
Since December 19, 2019, Cabio Biotech (Wuhan)'s market cap has decreased from 5.54B to 3.25B, a decrease of -41.41%. That is a compound annual growth rate of -8.24%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 3.25B | -16.41% |
| Dec 31, 2025 | 3.88B | 21.24% |
| Dec 31, 2024 | 3.20B | 6.31% |
| Dec 29, 2023 | 3.01B | -44.60% |
| Dec 30, 2022 | 5.44B | -26.24% |
| Dec 31, 2021 | 7.37B | 55.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 19, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Yantai Zhenghai Biotechnology | 3.49B |
| Beijing Kawin Technology Share-Holding | 3.46B |
| Shanghai Model Organisms Center | 3.29B |
| Guangdong VTR Bio-Tech | 3.12B |
| Shanghai Hile Bio-Technology | 3.06B |
| Suzhou Fushilai Pharmaceutical | 2.94B |
| Jiangsu Sihuan Bioengineering | 2.89B |
| Landfar Bio-medicine | 2.87B |